1. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115(5): 1111-1119. Web site. http://www.jci.org/articles/view/25102. Accessed August 14, 2016
2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science. 1993; 259(5091): 87-91. doi: 10.1126/science.7678183
3. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993; 268(35): 26055-26058. Web site. http://www.jbc.org/content/268/35/26055.long. Accessed August 14, 2016
4. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994; 91(11): 4854-4858. Web site. http://www.pnas.org/content/91/11/4854.short. Accessed August 14, 2016
5. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994; 94(4): 1543-1549. doi: 10.1172/JCI117495
6. Garvey WT, Maianu L, Hancock JA, Golichowski AM, Baron A. Gene expression of GLUT4 in skeletal muscle from insulinresistant patients with obesity, IGT, GDM, and NIDDM. Diabetes. 1992; 41(4): 465-475. doi: 10.2337/diab.41.4.465
7. Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem. 1991; 266(32): 21839-21845. Web site. http://www.jbc.org/content/266/32/21839.long. Ac-cessed August 14, 2016
8. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996; 45(7): 881-885. doi: 10.2337/diab.45.7.881
9. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab. 2000; 85(3): 1316-1319. doi: 10.1210/jcem.85.3.6417
10. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005; 42(6): 517-525. doi: 10.1159/000088261
11. Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011; 96(1): E146-E150. doi: 10.1210/jc.2010-1170
12. Lu MC, Yan ST, Yin WY, Koo M, Lai NS. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study. PLoS One. 2014; 9(7): e101528. doi: 10.1371/journal.pone.0101528
13. Su CC, Chen I, Young FN, Lian I. Risk of diabetes in patients with rheumatoid arthritis: a 12-year retrospective cohort study. J Rheumatol. 2013; 40(9): 1513-1518. doi: 10.3899/jrheum.121259
14. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol. 2002; 29(3): 462-466. Web site. http://www.jrheum. org/content/29/3/462.short. Accessed August 14, 2016
15. Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008; 58(7): 2105-2112. doi: 10.1002/art.23600
16. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108(24): 2957-2963. doi: 10.1161/01.CIR.0000099844.31524.05
17. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extra-articular feature of rheumatoid arthritis? Arthritis Rheum. 2002; 46(4): 862-873. doi: 10.1002/art.10089
18. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64(5): 765-766. doi: 10.1136/ard.2004.026534
19. Gonzalez-Gay MA, de Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24(1): 83-86. Web site. http://www.clinexprheumatol.org/abstract.asp?a=2793. Accessed August 14, 2016
20. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol. 2007; 20(4): 731-736. doi: 10.1177/039463200702000408
21. Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012; 14(3): R141. doi: 10.1186/ar3874
22. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-α antibody infliximab. Eur J Clin Invest. 2004; 34(9): 641-642. doi: 10.1111/j.1365-2362.2004.01390.x
23. Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC. Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: A case observation. Diabetes Care. 2006; 29(7): 1712-1713. doi: 10.2337/dc06-0636
24. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011; 305(24): 2525-2531. doi: 10.1001/jama.2011.878
25. Gupta-Ganguli M, Cox K, Means B, Gerling I, Solomon SS. Does therapy with anti-TNF-alpha improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011; 34(7): e121-e133. doi: 10.2337/dc10-1334